BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease

Clinical Immunology

Volumn 158, Issue 2, 2015, Pages 140-147

  Doerfler, Phillip A ^a   Nayak, Sushrusha ^b   Herzog, Roland W ^a   Morel, Laurence ^a   Byrne, Barry J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acid alpha glucosidase; BAFF; BLyS; Enzyme replacement therapy; Pompe disease

Indexed keywords

B CELL ACTIVATING FACTOR; DRUG ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; ANTIBODY; APRIL PROTEIN; GLUCAN 1,4 ALPHA GLUCOSIDASE; TNFSF13 PROTEIN, MOUSE; TNFSF13B PROTEIN, MOUSE;

ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SECRETING CELL; ANTIBODY TITER; ARTICLE; BONE MARROW; CELL COMPARTMENTALIZATION; CELL MATURATION; CONTROLLED STUDY; ENZYME REPLACEMENT; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; IMMUNE RESPONSE; IMMUNOTHERAPY; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENE DELETION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; GLYCOGEN STORAGE DISEASE TYPE II; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PROCEDURES;

ANIMALS; ANTIBODIES; B-CELL ACTIVATING FACTOR; DISEASE MODELS, ANIMAL; ENZYME REPLACEMENT THERAPY; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC THERAPY; GLUCAN 1,4-ALPHA-GLUCOSIDASE; GLYCOGEN STORAGE DISEASE TYPE II; MALE; MICE; MICE, KNOCKOUT; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84928633908     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.03.022     Document Type: Article

References (25)

1. Van der Ploeg A.T., Reuser A.J.J. Pompe's disease. Lancet 2008, 372:1342-1353.
2. Byrne B.J., Kishnani P.S., Case L.E., Merlini L., Müller-Felber W., Prasad S., et al. Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol. Genet. Metab. 2011, 103:1-11.
3. Lim J.-A., Li L., Raben N. Pompe disease: from pathophysiology to therapy and back again. Front. Aging Neurosci. 2014, 6:177.
4. Brooks D.A., Kakavanos R., Hopwood J.J. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol. Med. 2003, 9:450-453.
5. Banugaria S.G., Patel T.T., Mackey J., Das S., Amalfitano A., Rosenberg A.S., et al. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol. Genet. Metab. 2012, 105:677-680.
6. Banugaria S.G., Prater S.N., Ng Y.-K., Kobori J.A., Finkel R.S., Ladda R.L., et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet. Med. 2011, 13:729-736.
7. Wang J., Lozier J., Johnson G., Kirshner S., Verthelyi D., Pariser A., et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat. Biotechnol. 2008, 26:901-908.
8. Nicolino M., Byrne B., Wraith J.E., Leslie N., Mandel H., Freyer D.R., et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet. Med. 2009, 11:210-219.
9. Nayak S., Doerfler P.A., Porvasnik S.L., Cloutier D.D., Khanna R., Valenzano K.J., et al. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. PLoS One 2014, 9:e98336.
10. Elder M.E., Nayak S., Collins S.W., Lawson L.A., Kelley J.S., Herzog R.W., et al. B-cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J. Pediatr. 2013, 163. (847-854.e1).
11. Banugaria S.G., Prater S.N., McGann J.K., Feldman J.D., Tannenbaum J.A., Bailey C., et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet. Med. 2013, 15:123-131.
12. Messinger Y.H., Mendelsohn N.J., Rhead W., Dimmock D., Hershkovitz E., Champion M., et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet. Med. 2012, 14:135-142.
13. Mendelsohn N.J., Messinger Y.H., Rosenberg A.S., Kishnani P.S. Elimination of antibodies to recombinant enzyme in Pompe's disease. N. Engl. J. Med. 2009, 360:194-195.
14. Carson K.R., Focosi D., Major E.O., Petrini M., Richey E.a., West D.P., et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009, 10:816-824.
15. Shum K., Askanase A. Belimumab and the clinical data. Curr. Rheumatol. Rep. 2012, 14:310-317.
16. Baker K.P., Edwards B.M., Main S.H., Choi G.H., Wager R.E., Halpern W.G., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003, 48:3253-3265.
17. Parsons R.F., Yu M., Vivek K., Zekavat G., Rostami S.Y., Ziaie A.S., et al. Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF. Transplantation 2012, 93:676-685.
18. Gorbacheva V., Ayasoufi K., Fan R., Baldwin W.M., Valujskikh A. B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) mediate CD40-independent help by memory CD4 T cells. Am. J. Transplant. 2015, 15:346-357.
19. Mariño E., Walters S.N., Villanueva J.E., Richards J.L., Mackay C.R., Grey S.T. BAFF regulates activation of self-reactive T cells through B-cell dependent mechanisms and mediates protection in NOD mice. Eur. J. Immunol. 2014, 44:983-993.
20. Kyaw T., Cui P., Tay C., Kanellakis P., Hosseini H., Liu E., et al. BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-/-) mice. PLoS One 2013, 8:e60430.
21. Vincent F.B., Saulep-Easton D., Figgett W.A., Fairfax K.A., Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013, 24:203-215.
22. Mackay F., Leung H. The role of the BAFF/APRIL system on T cell function. Semin. Immunol. 2006, 18:284-289.
23. Chung J.B., Silverman M., Monroe J.G. Transitional B cells: step by step towards immune competence. Trends Immunol. 2003, 24:342-348.
24. Scholz J.L., Crowley J.E., Tomayko M.M., Steinel N., O'Neill P.J., Quinn W.J., et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15517-15522.
25. Fraites T.J., Schleissing M.R., Shanely R.A., Walter G.A., Cloutier D.A., Zolotukhin I., et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol. Ther. 2002, 5:571-578.